[Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Kvasnicka T;Kvasnicka T
  • Source:
    Casopis lekaru ceskych [Cas Lek Cesk] 2005; Vol. 144 (2), pp. 81-4; discussion 85.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't; Review
  • Language:
    Czech
  • Additional Information
    • Transliterated Title:
      Endokanabinoidy--nová moznost v lécbĕ metabolického syndromu a odvykáiní kourení.
    • Source:
      Publisher: Ceskoslovenska Lekarska Spolecnost Country of Publication: Czech Republic NLM ID: 0004743 Publication Model: Print Cited Medium: Print ISSN: 0008-7335 (Print) Linking ISSN: 00087335 NLM ISO Abbreviation: Cas Lek Cesk Subsets: MEDLINE
    • Publication Information:
      Original Publication: Praha : Ceskoslovenska Lekarska Spolecnost
    • Subject Terms:
      Cannabinoid Receptor Antagonists* ; Endocannabinoids* ; Smoking Cessation*; Cannabinoid Receptor Modulators/*metabolism ; Metabolic Syndrome/*metabolism ; Piperidines/*therapeutic use ; Pyrazoles/*therapeutic use; Arachidonic Acids/metabolism ; Cannabinoid Receptor Modulators/antagonists & inhibitors ; Humans ; Metabolic Syndrome/therapy ; Polyunsaturated Alkamides ; Rimonabant ; Smoking/metabolism ; Weight Loss
    • Abstract:
      Development of the metabolic syndrome results from the interaction of genetic and environmental factors. Metabolic syndrome together with smoking represents risk factors for the development of cardiovascular complications. They may result from the hyperstimulation of the endocannabinoid system. The CB1 receptor has been assumed to play an important role in the endocannabionoid system. It is abundantly expressed in the brain, and in other parts of human body such as in the fat tissue. Rimonabant is a selective blocker of cannabinoid-1 (CB1) receptors and participates in the regulation of impaired endocannabinoid system. In the overweight humans, it stimulates sustained reduction of the body weight, girth size and it improves lipid and glucose metabolism. Rimonabant also reduces nicotine self-administration and may be effective not only as an aid for smoking cessation but also in the prevention of body weight increase related to the smoking cessation as it was documented in Rio-Lipids and Stratus-us studies.
    • Number of References:
      26
    • Accession Number:
      0 (Arachidonic Acids)
      0 (Cannabinoid Receptor Antagonists)
      0 (Cannabinoid Receptor Modulators)
      0 (Endocannabinoids)
      0 (Piperidines)
      0 (Polyunsaturated Alkamides)
      0 (Pyrazoles)
      RML78EN3XE (Rimonabant)
      UR5G69TJKH (anandamide)
    • Publication Date:
      Date Created: 20050406 Date Completed: 20050503 Latest Revision: 20181201
    • Publication Date:
      20240829
    • Accession Number:
      15807291